Broaddus RR - Search Results

1

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. Slomovitz BM, et al. Among authors: broaddus rr. Cancer. 2010 Dec 1;116(23):5415-9. doi: 10.1002/cncr.25515. Epub 2010 Aug 2. Cancer. 2010. PMID: 20681032 Free PMC article. Clinical Trial.

2

Low-grade ovarian cancer in an adolescent patient.

Parker LP, Ramirez PT, Broaddus R, Sightler S, Wolf JK. Parker LP, et al. Gynecol Oncol. 2001 Jan;80(1):104-6. doi: 10.1006/gyno.2000.6020. Gynecol Oncol. 2001. PMID: 11136580

3

Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common--now what?

Lu KH, Broaddus RR. Lu KH, et al. Among authors: broaddus rr. Gynecol Oncol. 2001 Aug;82(2):221-2. doi: 10.1006/gyno.2001.6332. Gynecol Oncol. 2001. PMID: 11531270 No abstract available.

4

Wolffian duct tumors: case reports and review of the literature.

Ramirez PT, Wolf JK, Malpica A, Deavers MT, Liu J, Broaddus R. Ramirez PT, et al. Gynecol Oncol. 2002 Aug;86(2):225-30. doi: 10.1006/gyno.2002.6739. Gynecol Oncol. 2002. PMID: 12144833 Review.

5

PTEN expression in tamoxifen-associated endometrial cancers.

Holtz D, Ramondetta LM, Burke TW, Palazzo JP, Dunton CJ, Atkinson EN, Broaddus RR. Holtz D, et al. Among authors: broaddus rr. Anticancer Res. 2002 Sep-Oct;22(5):2945-8. Anticancer Res. 2002. PMID: 12530022

6

Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma.

Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM, Walker CL. Houston KD, et al. Among authors: broaddus rr. Cancer Res. 2003 Mar 15;63(6):1221-7. Cancer Res. 2003. PMID: 12649180

7

Sarcomatoid carcinoma of the cervix.

Brown J, Broaddus R, Koeller M, Burke TW, Gershenson DM, Bodurka DC. Brown J, et al. Gynecol Oncol. 2003 Jul;90(1):23-8. doi: 10.1016/s0090-8258(03)00200-2. Gynecol Oncol. 2003. PMID: 12821337

8

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.

Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Schmandt RE, et al. Cancer. 2003 Aug 15;98(4):758-64. doi: 10.1002/cncr.11561. Cancer. 2003. PMID: 12910520 Free article.

9

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.

Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. Ramondetta LM, et al. Gynecol Oncol. 2003 Sep;90(3):529-36. doi: 10.1016/s0090-8258(03)00332-9. Gynecol Oncol. 2003. PMID: 13678720 Clinical Trial.

10

Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.

Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Tanyi JL, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45. Clin Cancer Res. 2003. PMID: 14506139

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

351 results

Search Page